Wasatch BioLabs has announced a co-marketing agreement with Agilent Technologies to expand access to its Direct Targeted Methylation Sequencing (dTMS) platform. The partnership integrates Agilent’s SureSelect and Avida enrichment chemistries with Wasatch BioLabs’ Oxford Nanopore-based native-read workflow, aiming to streamline high-throughput targeted sequencing for research use only (RUO) and translational settings. The announcement marks a […]
Detect-ION, a diagnostics-focused startup based in Tampa, Florida, has announced a collaborative project with the Infectious Diseases Division at Mayo Clinic Florida to develop a non-invasive breath test for detecting Pseudomonas aeruginosa, a leading cause of pneumonia in vulnerable patient populations. Funded through the Mayo Clinic Advanced Innovation Research program, the project aims to address […]
Bioretec Ltd, the Finland-based medical device developer specializing in fully biodegradable orthopedic implants, has received Breakthrough Device Designation from the U.S. Food and Drug Administration for its RemeOs DrillPin. The designation applies to the use of the biodegradable magnesium-alloy device in pediatric and adult bone fixation procedures, including epimetaphyseal fractures in children over two years […]
Personalis, Inc. has reported pivotal findings from its NeXT Personal assay in a new Cell publication, highlighting the test’s ability to detect molecular residual disease in stage I to III non-small cell lung cancer. The study, part of the TRACERx initiative and led by Professor Charles Swanton of the Francis Crick Institute and University College […]
Bendit Technologies has secured 510(k) clearance from the U.S. Food and Drug Administration for its Bendit17 steerable microcatheter, a device the company describes as the smallest steerable microcatheter available for use in neurovascular and peripheral endovascular interventions. With U.S. commercialization slated to begin in January 2026, the Israel-based medical device manufacturer is also pursuing regulatory […]
Subsense, Inc. has raised an additional $10 million in funding to accelerate the development of its non-surgical, nanoparticle-based brain-computer interface (BCI), bringing its total funding to $27 million. The financing, led by Golden Falcon Capital, follows early successes in nanoparticle design, in vitro signal stimulation, and the construction of a bio-integrated hardware-software platform intended to […]
Prelude Corporation has announced the first independent validation of AidaBreast, a multi-omic diagnostic test developed to predict both locoregional recurrence risk and individualized radiation therapy benefit in early-stage hormone receptor-positive, HER2-negative invasive breast cancer. The study, conducted at Royal Melbourne Hospital and presented at the San Antonio Breast Cancer Symposium 2025, evaluated over 400 women […]
